Sofinnova Investments’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sofinnova Investments’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-408,819	Closed	-$44.6M	–	68
2023 Q1	$44.6M	Sell	408,819 -4,354	-1%	-$481K	2.85%	9
2022 Q4	$47M	Buy	+413,173	New	+$34.3M	2.79%	9
2022 Q3	–	Sell	-100,297	Closed	-$8M	–	71
2022 Q2	$8M	Sell	100,297 -132,597	-57%	-$12.6M	0.67%	30
2022 Q1	$24.5M	Buy	232,894 +11,102	+5%	+$1.08M	1.86%	13
2021 Q4	$23.9M	Buy	221,792 +64,305	+41%	+$7.01M	1.4%	19
2021 Q3	$17.3M	Buy	+157,487	New	+$16.3M	1.02%	23
2021 Q2	–	Sell	-133,997	Closed	-$12.3M	–	81
2021 Q1	$12.3M	Sell	133,997 -79,393	-37%	-$6.7M	0.74%	31
2020 Q4	$15.6M	Buy	+213,390	New	+$15.9M	0.93%	24
2020 Q3	–	Sell	-252,958	Closed	-$14.1M	–	94
2020 Q2	$14.1M	Buy	+252,958	New	+$10.8M	0.89%	26

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sofinnova Investments's HZNP Position: Q2 2023 in Review

Sofinnova Investments sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 408,819 shares — an estimated $44.6M sold.

Sofinnova Investments first reported a position in HZNP in Q2 2020 and held it in 9 quarters. The position peaked at $47M in Q4 2022. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Sofinnova Investments reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Sofinnova Investments sold 408,819 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $44.6M.
Sofinnova Investments first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 9 quarters.
Sofinnova Investments's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $47M in Q4 2022.
517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.